Literature DB >> 9637161

Recombinant human granulocyte colony-stimulating factor attenuates inflammatory responses in septic patients with neutropenia.

K Ishikawa1, H Tanaka, T Matsuoka, T Shimazu, T Yoshioka, H Sugimoto.   

Abstract

OBJECTIVE: The objective of this study was to determine the effects of recombinant human granulocyte colony-stimulating factor (rhG-CSF) administration in septic patients with neutropenia.
METHODS: Twenty consecutive septic patients were administered rhG-CSF subcutaneously (2 microg x kg(-1) x d(-1)) for 5 days (group G). They were compared with 14 septic patients treated earlier without rhG-CSF (group N). All patients in both groups met the criteria of total leukocyte count (TLC) less than 5,000/mm3 and C-reactive protein (CRP) more than 10 mg/dL. Changes in TLC, absolute neutrophil count (ANC), CRP, respiratory index (RI), Acute Physiology and Chronic Health Evaluation (APACHE) II score, and Goris's Multiple Organ Failure (MOF) index were evaluated. In addition, nucleated cell count (NCC), differentiation in bone marrow aspiration, neutrophil phagocytic and bactericidal activity, serum concentrations of interleukin-6 (IL-6) and IL-8 as inflammatory markers, and plasma concentration of leukocyte elastase (LE) as an indicator of the tissue injury were evaluated in group G.
RESULTS: In group G, TLC, ANC, NCC, and neutrophil functions increased significantly, whereas CRP, IL-6, and IL-8 decreased reciprocally. There was no deterioration of LE and RI. Consequently, the APACHE II score and MOF index improved. In group N, however, CRP showed no change concomitant with the APACHE II score and MOF index.
CONCLUSION: Administration of rhG-CSF attenuates inflammatory responses without inducing tissue injury in septic patients with neutropenia.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9637161     DOI: 10.1097/00005373-199806000-00018

Source DB:  PubMed          Journal:  J Trauma        ISSN: 0022-5282


  8 in total

Review 1.  Colony-stimulating factors for the management of neutropenia in cancer patients.

Authors:  David C Dale
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  Adjunctive Therapies for Sepsis and Septic Shock.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-08       Impact factor: 3.725

Review 3.  Toward improving mucosal barrier defenses: rhG-CSF plus IgG antibody.

Authors:  Aryeh Simmonds; Edmund F LaGamma
Journal:  Indian J Pediatr       Date:  2006-11       Impact factor: 1.967

4.  Granulocyte colony-stimulating factor improves deficient in vitro neutrophil transendothelial migration in patients with advanced liver disease.

Authors:  Carmen Fiuza; Magdalena Salcedo; Gerardo Clemente; Jose M Tellado
Journal:  Clin Diagn Lab Immunol       Date:  2002-03

5.  Perioperative recombinant human granulocyte colony-stimulating factor (Filgrastim) treatment prevents immunoinflammatory dysfunction associated with major surgery.

Authors:  Christian Schneider; Sonja von Aulock; Siegfried Zedler; Christian Schinkel; Thomas Hartung; Eugen Faist
Journal:  Ann Surg       Date:  2004-01       Impact factor: 12.969

6.  Bactericidal activity response of blood neutrophils from critically ill patients to in vitro granulocyte colony-stimulating factor stimulation.

Authors:  Kun Yang; Elie Azoulay; Lynda Attalah; Jean-Ralph Zahar; Andry Van de Louw; Charles Cerf; Claude-James Soussy; Philippe Duvaldestin; Laurent Brochard; Christian Brun-Buisson; Alain Harf; Christophe Delclaux
Journal:  Intensive Care Med       Date:  2003-01-23       Impact factor: 17.440

Review 7.  Administration of signalling molecules dictates stem cell homing for in situ regeneration.

Authors:  Xuan Li; Xiao-Tao He; Yuan Yin; Rui-Xin Wu; Bei-Min Tian; Fa-Ming Chen
Journal:  J Cell Mol Med       Date:  2017-08-02       Impact factor: 5.310

8.  The Effects of Granulocyte Colony-Stimulating Factor (G-CSF) in Pre-Clinical Models of Infection and Acute Inflammation.

Authors:  John C Marshall
Journal:  Sepsis (Boston)       Date:  1998
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.